This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


David Cole, PhD
Collaboration Research Group Leader at Immunocore


Dr David Cole currently leads Collaboration Research at Immunocore, a privately funded biotech just outside of Oxford that is developing novel bispecific T cell engagers using engineered T cell receptor technology. Before moving to Immunocore in 2017, David spent a number of years in academia, completing his PhD at Oxford University in 2007, before setting up his own laboratory at Cardiff University in 2009. During his academic career, David used a variety of molecular approaches (X-ray crystallography, biophysics, protein engineering) to better understand the nature of T cell antigen recognition, which is governed by the interaction between the T cell receptor and peptide-human leukocyte antigen. In his current role at Immunocore, he is now applying this fundamental understanding of T cell receptors to help develop novel drugs to treat cancer.

Agenda Sessions

  • LIVE Moderated Panel Discussion and Q&A Including Audience Interaction with Speakers from On-Demand SESSION #5: BISPECIFIC ANTIBODIES: NEW APPROACHES AND CASE STUDIES - To prepare for this discussion/Q&A, attendees should view the presentations from Session #5 in the Watch On-Demand Sessions Tab prior to this session

  • The Distinct Binding Footprints of Bispecific T cell Receptors (TCR) and TCR-mimic Antibodies Underpin pHLA Selectivity

    On Demand